A little brief of The Pharmacovigilance Program of India (PvPI), It was launched with the mission to promote patient safety. All over India experiencing Adverse Drug Reactions (ADRs) and send reports to NCC-PvPI working in collaboration with the global ADR monitoring center (WHO-UMC), Sweden to contribute in the global ADRs database.
The national coordinating center (NCC) for PvPI is the Indian Pharmacopoeia Commission (IPC), Ghaziabad which monitors the ADRs among the country population and helps the regulatory authority of India (CDSCO) in taking decision for safe use of medicines.
As government mandated to report ADRs and around 80 corporate hospitals have begun reporting adverse drug reactions (ADRs) as part of their pharmacovigilance activities to promote monitoring of ADRs effectively by healthcare institutions to Pharmacovigilance Programme of India (PvPI).
The national coordinating center (NCC) has also signed a Memorandum of Understanding (MoU) with National Accreditation Board for Hospitals and Healthcare Providers (NABH) to promote monitoring of ADRs through hospitals and nursing homes. Relevant clinical data can be generated with the support of the hospitals who will report ADRs and coordinate with the respective adverse drug reaction monitoring centers (AMCs).
Auditing of healthcare institutions has also begun by the Central Drugs Standard Control Organisation (CDSCO) with IPC collaboration on aspects like SOPs and causality assessment to inspect the working of Adverse Drug Reaction Monitoring Centres (AMCs) in the country.
IPC took an initiative to generate awareness about the ADRs in hospitals or medical institutes with placing effective surveillance system for detection of adverse drug reactions. In July 2010, CDSCO under the Union health ministry had introduced a nation-wide PvPI.
